BioParadox: The future of point-of-care cell
therapies for cardiovascular disease.
BioParadox is innovating the use of Platelet-Cell Therapy™
(PCT) for the treatment of cardiovascular disease.
The company's first products, RevaTen™ and VitaKine™,
are proprietary formulations of PCT that accelerate the
body's natural healing process.

Board of Directors »
Allan Mishra, MD, Jay Watkins, MBA, Todd Brinton, MD, Michael Kleine

Scientific Advisory Board »
Paul Yock, MD, Robert Robbins, MD,
Doug Losordo, MD, Warren Sherman, MD

NEWS
BioParadox featured in The MedTech Strategist
BioParadox initiates BioBipass™ trial with human blood processing
BioParadox Announces Partnership with Fogarty Institute for Innovation
US Patent Office issues Peripheral Vascular Disease claims to BioParadox
Regenerative Medicine Company BioParadox adds Healthcare and Medical Device Expert, Michael Kleine, to its Board of Directors
BioParadox presents at TCT in San Francisco. Strategies for Cardiovascular Repair: Stem Cells and Beyond
VitaKine Platelet Cell Therapy (PCT) Improves Cardiac Function
BioParadox presents at New York cardiovascular cell therapy meeting
RevaTen™ PCT potential treatment for heart attacks »
BioParadox inks deal with Thermogenesis »

You are viewing the non-Flash version of our website
Get Adobe Flash player

Board of Directors

Allan Mishra, MD
Dr. Mishra pioneered the use of platelet rich plasma for sports related injuries. He is the sole inventor on ten issued patents and dozens of pending patents. He is also a board certified orthopedic surgeon and sports medicine specialist. His basic science and clinical research has been presented in dozens of forums worldwide and has been published in elite journals.

Todd Brinton, MD
Dr. Brinton is a Clinical Assistant Professor of Medicine (Cardiology) and Lecturer in Bioengineering at Stanford University. He is an attending interventional cardiologist at both Stanford University Medical Center and the Palo Alto VA Medical Center. He is also the fellowship director for the program in biodesign innovation and co-director of the graduate class in biodesign innovation.

Jay Watkins, MBA
Jay is a Managing Director at De Novo Ventures. Prior to joining De Novo in 2002, Jay was a co-founder of Origin Medsystems, a venture-funded medical technology start-up that was purchased by Eli Lilly & Company in 1992. When Eli Lilly divested its medical device businesses to form Guidant in 1995, he became a member of the corporation's management committee, serving in this role from 1995-2002. During this time, he served as president of numerous divisions, including the Minimally Invasive Surgery Group. In addition, Jay was the President of Compass, Guidant Corporation's corporate business development and new ventures group. Prior to founding Origin, Jay held management positions in several start-ups, including Microgenics Corporation, and was a consultant with the international consulting firm of McKinsey & Company. He has been a member of the board of directors of several public companies, including Gynecare, Cardiogenesis, and Rita Medical. Jay received his MBA from Harvard University and his undergraduate degree from Stanford University

Michael Kleine
Michael has more than 25 years experience in the medical device and healthcare industries. He is presently President & Chief Executive officer of EndoGastric Solutions, a pioneer in Natural Orifice Surgery (NOS) for the treatment of upper gastrointestinal diseases. Previous executive experience includes President and CEO of Biosensors International Group, Ltd., a publicly traded company in the interventional cardiology and critical care markets, President and CEO of MicroVention, a start-up focused on the minimally invasive treatment of cerebral brain aneurysms, which was acquired by Terumo, President and CEO of Thermo Cardiosystems Inc., an $80 million manufacturer and distributor of left ventricular assist systems, incision and blood coagulation devices, that was acquired by Thoratec, and President and CEO of Sorin Biomedical Inc., a $54 million manufacturer and distributor of cardiopulmonary equipment that merged with Cobe, Inc.

Scientific Advisory Board

Doug Losordo, MD
Dr. Losordo is the director of the Feinberg Cardiovascular Research Institute and director of the program in Cardiovascular Regenerative Medicine at Northwestern. Dr. Losordo is currently Associate Editor of Circulation Research and serves on the editorial boards of Circulation, Vascular Medicine, and Stem Cells, among others.

Robert Robbins, MD
Dr. Robbins is the Professor and Chairman of the Department of Cardiothoracic Surgery. He has been a member of the faculty at Stanford University School of Medicine since 1993. He serves as Director of the Stanford Cardiovascular Institute, Director of the Heart, Heart/Lung, and Lung Transplant programs, and is the Director of the Cardiothoracic Transplantation Laboratory.

Warren Sherman, MD
Dr. Sherman is the director of Cardiac Cell-Based Endovascular Therapies Center for Interventional Vascular Therapy New York-Presbyterian Hospital/Columbia University Medical Center. He is also the director of the Conference on Cell Therapy for Cardiovascular Disease.

Paul Yock, MD
Dr. Yock is the Martha Meier Weiland Professor of Medicine and Mechanical Engineering (by courtesy) and Founding Co-Chair of Stanford's new Department of Bioengineering. He also holds a courtesy appointment on Operations, Information and Technology in the Stanford School of Business. Dr. Yock is internationally known for his work in inventing, developing and testing new devices, including the Rapid Exchange™ balloon angioplasty system, which is now the primary system in use worldwide.

Contact us

Email
info@BioParadox.com